Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer Metabolism Agent, CPI-613, in Rat and Human

Vijay Bhasker Reddy, Lakmal Boteju, Asela Boteju, Li Shen, Kelem Kassahun, Nageshwar Reddy, Adrian Sheldon, Sanjeev Luther and Ke Hu
Drug Metabolism and Disposition April 2022, 50 (4) 361-373; DOI: https://doi.org/10.1124/dmd.121.000726
Vijay Bhasker Reddy
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lakmal Boteju
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asela Boteju
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Shen
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelem Kassahun
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nageshwar Reddy
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian Sheldon
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjeev Luther
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke Hu
Rafael Pharmaceuticals, Cranbury, New Jersey (V.B.R., L.B., A.B., N.R., S.L., K.H.); Frontage Laboratories, Exton, Pennsylvania (L.S., K.K.); and Charles River Laboratories, Worcester, Massachusetts (A.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

CPI-613, an inhibitor of pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (KGDH) enzymes, is currently in development for the treatment of pancreatic cancer, acute myeloid leukemia, and other cancers. CPI-613 is an analog of lipoic acid, an essential cofactor for both PDH and KGDH. Metabolism and mass balance studies were conducted in rats after intravenous administration of [14C]-CPI-613. CPI-613 was eliminated via oxidative metabolism followed by excretion of the metabolites in feces (59%) and urine (22%). β-Oxidation was the major pathway of elimination for CPI-613. The most abundant circulating components in rat plasma were those derived from β-oxidation. In human hepatocytes, CPI-613 mainly underwent β-oxidation (M1), sulfur oxidation (M2), and glucuronidation (M3). The Michaelis-Menten kinetics (Vmax and Km) of the metabolism of CPI-613 to these three metabolites predicted the fraction metabolized leading to the formation of M1, M2, and M3 to be 38%, 6%, and 56%, respectively. In humans, after intravenous administration of CPI-613, major circulating species in plasma were the parent and the β-oxidation derived products. Thus, CPI-613 metabolites profiles in rat and human plasma were qualitatively similar. β-Oxidation characteristics and excretion patterns of CPI-613 are discussed in comparison with those reported for its endogenous counterpart, lipoic acid.

SIGNIFICANCE STATEMENT This work highlights the clearance mechanism of CPI-613 via β-oxidation, species differences in their ability to carry out β-oxidation, and subsequent elimination routes. Structural limitations for completion of terminal cycle of β-oxidation is discussed against the backdrop of its endogenous counterpart lipoic acid.

Footnotes

    • Received October 11, 2021.
    • Accepted January 20, 2022.
  • This work received no external funding.

  • V.B.R., L.B., A.B., N.R., J.H., and S.L. are paid employees of Rafael Pharmaceuticals Inc. L.S., K.K., and A.S. are paid employees of contract research organizations Frontage Laboratories or Charles River Laboratories.

  • https://dx.doi.org/10.1124/dmd.121.000726.

  • Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 50 (4)
Drug Metabolism and Disposition
Vol. 50, Issue 4
1 Apr 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro and In Vivo Metabolism of a Novel Antimitochondrial Cancer Metabolism Agent, CPI-613, in Rat and Human
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

β-Oxidation of CPI-613 in Rat and Human

Vijay Bhasker Reddy, Lakmal Boteju, Asela Boteju, Li Shen, Kelem Kassahun, Nageshwar Reddy, Adrian Sheldon, Sanjeev Luther and Ke Hu
Drug Metabolism and Disposition April 1, 2022, 50 (4) 361-373; DOI: https://doi.org/10.1124/dmd.121.000726

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

β-Oxidation of CPI-613 in Rat and Human

Vijay Bhasker Reddy, Lakmal Boteju, Asela Boteju, Li Shen, Kelem Kassahun, Nageshwar Reddy, Adrian Sheldon, Sanjeev Luther and Ke Hu
Drug Metabolism and Disposition April 1, 2022, 50 (4) 361-373; DOI: https://doi.org/10.1124/dmd.121.000726
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Instrumentation
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • ABBREVIATIONS
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P450 cell lines for xenobiotic metabolite generation
  • New Dog, Cat, and Pig P450 2J Enzymes
  • Human ADME properties of abrocitinib
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics